A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma

Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma. To prospectively map the landscape of resistance to this investigational regimen, we utilized a series of gain- and loss-of-function forward genetic screens to identify modulators of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Hayes, Tikvah K., Luo, Flora, Cohen, Ofir, Goodale, Amy B., Lee, Yenarae, Pantel, Sasha, Bagul, Mukta, Piccioni, Federica, Root, David E., Garraway, Levi A., Meyerson, Matthew, Johannessen, Cory M.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227487/
https://ncbi.nlm.nih.gov/pubmed/30819666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-2711
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares